Our findings demonstrate that iNs from patients with SMA and IGHMBP2-related disorders exhibit morphological irregularities, which can be alleviated by restoring functional protein (SMN1 and IGHMBP2, respectively) through AAV9-mediated gene therapies. This evidence concerns the gene SMN1 and proximal spinal muscular atrophy.